Advertisement
Screener

ENVERIC BIOSCIENCES, INC. (ENVB) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)

1.4 / 5 stars · 20/74 Roast Me

ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)

ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) of 590.87 thousand shares for the 12-month period ending 2016-12-31, per its 10-K/A filed 2017-04-04.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease · last filed 2017-04-04

  • ENVERIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, period increase (decrease) for fiscal 2016 was 590.87K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) 12 month
2016-12-31590.87K shares
10-K/A · filed 2017-04-04
2015-12-3183.19K shares
10-KT · filed 2016-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
Pulmatrix, Inc. (PULM)United States$0.006B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
EXICURE, INC. (XCUR)United States$0.008B-1.54